Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jenta Alexander

Nurse Practitioner, Family Milwaukee, WI Nurse Practitioner

NPI 1023562758 CMS profile 11069977

7235 W Appleton Ave, Milwaukee, WI 53216

Open in the dashboard

General payments

$11,542

628 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenta Alexander of Milwaukee, WI is reported in the CMS Open Payments database as having received $11,542 across 628 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,611 183
2024 General $2,868 161
2023 General $2,333 137
2022 General $1,614 91
2021 General $1,115 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenta Alexander
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jenta Alexander were reported at $3,611. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jenta Alexander Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,115 $124 $35–$379 $132
2022 $1,614 $141 $44–$430 $149
2023 $2,333 $154 $49–$476 $160
2024 $2,868 $165 $51–$504 $164
2025 $3,611 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,741 102 payments
  2. AstraZeneca Pharmaceuticals LP $1,463 80 payments
  3. Pfizer Inc. $1,322 76 payments
  4. Lilly USA, LLC $786 49 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $712 36 payments
  6. Otsuka America Pharmaceutical, Inc. $499 37 payments
  7. Ironwood Pharmaceuticals, Inc $434 23 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $404 19 payments
  9. Novo Nordisk Inc $396 24 payments
  10. Biohaven Pharmaceuticals, Inc. $393 12 payments
  11. Other $3,393 170 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,395 624 payments
  2. Education $146 4 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Pain $932 54 payments
  2. ZAVZPRET $814 48 payments
  3. Kerendia $712 36 payments
  4. UBRELVY $679 35 payments
  5. QULIPTA $557 27 payments
  6. FARXIGA $548 33 payments
  7. NURTEC ODT Primary Care $525 18 payments
  8. AIRSUPRA $505 23 payments
  9. REXULTI $442 33 payments
  10. Linzess $434 23 payments
  11. Other $8,867 508 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 156 drugs

Part D claims

11,077

Median for Nurse Practitioner: 389

Drug cost

$1,151,137

Median for Nurse Practitioner: $21,885

Branded share of claims

29.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 210 $139,343
Farxiga Dapagliflozin Propanediol Brand 164 $111,518
Jardiance Empagliflozin Brand 146 $106,297
Ozempic Semaglutide Brand 96 $102,538
Trulicity Dulaglutide Brand 79 $89,935
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 101 $65,829
Xifaxan Rifaximin Brand 16 $52,184
Eliquis Apixaban Brand 79 $49,782
Spiriva Handihaler Tiotropium Bromide Brand 55 $31,087
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 38 $29,043

The 10 drugs with the highest cost, of 156 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$9,387

Of which drugs: $694

Medicare patients

54

Average age 57

Services billed

255

29 women, 25 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Diabetes 41%
COPD 30%
Chronic kidney disease 28%
Arthritis 28%
Heart failure 22%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 42 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LINZESS
  • Ironwood Pharmaceuticals, Inc $179
  • AbbVie, Inc. $69
$248 210 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $151
  • Lilly USA, LLC $54
$205 146 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $171
$171 — —
VRAYLAR
  • AbbVie, Inc. $164
$164 — —
NURTEC ODT
  • PFIZER INC. $153
$153 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 42 with Patron

Records

628 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record